Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Gliosarcoma 2Glioblastoma 2Central Nervous System Neoplasms 2Brain Neoplasms 2Oligodendroglioma 1Neoplasm Metastasis 1Ependymoma 1Astrocytoma 1

Interventions

Magnetic Resonance Spectroscopy 9X-Rays 6Specimen Handling 6Phantoms, Imaging 6Nuclear Medicine Department, Hospital 5Temozolomide 4Carmustine 4Biopsy 4ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2olaparib 2larotrectinib 2ivosidenib 2erdafitinib 2ensartinib 2Vemurafenib 2Surgical Procedures, Operative 2Radiotherapy 2Lapatinib 2LY3023414 2Filgrastim 2Cyclophosphamide 2Congresses as Topic 2Cisplatin 2Bevacizumab 22,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 2veliparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Ependymoma × Ethanol × Clear all
NCT00009854 2013-11-06

Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm

National Cancer Institute (NCI)

Phase 1/2 Unknown
CNSSarcoma

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Neoplasm Metastasis, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡